达雷妥尤单抗联合硼替佐米和地塞米松治疗既往接受过治疗的多发性骨髓瘤(CASTOR)的总生存期:一项随机、开放标签、III期试验
CASTOR研究最终分析显示,在中位随访72.6个月时,达雷妥尤单抗联合硼替佐米和地塞米松(D-Vd)较单纯Vd显著延长复发或难治性多发性骨髓瘤患者的总生存期(HR 0.74,95%CI 0.59-0.92,P=0.0075),中位OS分别为49.6个月和38.5个月。
要点
- D-Vd较Vd显著改善OS,HR 0.74(95%CI 0.59-0.92,P=0.0075)。
- 中位OS:D-Vd组49.6个月 vs Vd组38.5个月。
- 一线既往治疗亚组OS获益最大。
核心结论
- D-Vd显著延长复发或难治性多发性骨髓瘤患者的总生存期,既往仅接受一线治疗的患者OS获益最大。
- 结合POLLUX研究结果,首次证实含达雷妥尤单抗方案在复发或难治性多发性骨髓瘤中具有OS获益。
研究设计与样本
- CASTOR为多中心、随机、开放标签、III期研究。
- eligible患者为既往接受≥1线治疗者,随机接受Vd(最多8周期)联合或不联合达雷妥尤单抗(至疾病进展)。
- 主要分析阳性后经方案修订,Vd组患者疾病进展后可接受达雷妥尤单抗单药治疗。
主要发现
- 中位随访72.6个月(范围0.0-79.8)时,D-Vd组较Vd组显著改善OS(HR 0.74,95%CI 0.59-0.92,P=0.0075)。
- D-Vd组中位OS为49.6个月,Vd组为38.5个月。
- 预设亚组分析显示,多数亚组中D-Vd较Vd具有OS优势,包括年龄≥65岁、既往1或2线治疗、国际分期系统III期、高危细胞遗传学异常及既往硼替佐米治疗患者。
- D-Vd组较Vd组最常见的(≥10%)3/4级治疗中出现的不良事件:血小板减少46.1% vs 32.9%,贫血16.0% vs 16.0%,中性粒细胞减少13.6% vs 4.6%,淋巴细胞减少10.3% vs 2.5%,肺炎10.7% vs 10.1%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS: CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. RESULTS: At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). CONCLUSION: D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).
引用
- Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022. PMID: 36413710. doi:10.1200/JCO.21.02734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。